Straka C, et al. - Via a post-hoc analysis of two phase III trials that recruited patients with newly diagnosed multiple myeloma, the experts investigated the impact of age and treatment factors on the effect of bortezomib consolidation on progression-free survival (PFS) after the autologous stem cell transplantation (ASCT). On the basis of the age, the patients were randomized into two trial groups (18–60 {n = 202} or 61–75 years {n = 155}). Among older and younger patients who received previous treatment of differing intensity, bortezomib consolidation seemed to balance the outcomes after ASCT suggesting that the effect of consolidation could be relative and could rely on the structure and intensity of induction and high-dose therapy. Hence, greater PFS benefit from bortezomib consolidation could be encountered by older patients who received less intensive prior treatment.